Inhibiting GLUTtony in cancer

Sarah M Chang; Matthew G Vander Heiden

doi:10.1016/j.chembiol.2022.03.004

Inhibiting GLUTtony in cancer

Cell Chem Biol. 2022 Mar 17;29(3):353-355. doi: 10.1016/j.chembiol.2022.03.004.

Authors

Sarah M Chang¹, Matthew G Vander Heiden²

Affiliations

¹ Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
² Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: mvh@mit.edu.

PMID: 35303439
DOI: 10.1016/j.chembiol.2022.03.004

Abstract

In this issue of Cell Chemical Biology, Olszewski et al. (2022) address the challenge of developing small molecules to inhibit glucose uptake in cancer. They characterize a novel pan-GLUT inhibitor that suppresses tumor growth and uncover how cancer cells can adapt to glucose restriction.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Biological Transport
Glucose
Humans
Neoplasms* / drug therapy

Substances

Glucose

Abstract

Publication types

MeSH terms

Substances

Grants and funding